Enteral Home Use Syringes Market

USD 350.4 million in 2026 to USD 702.3 million by 2036, at a 7.2% CAGR.

• As per Fact.MR analysis, the enteral home use syringes market was valued at USD 326.9 million in 2025.
• Demand will grow from USD 350.4 million in 2026 to USD 702.3 million by 2036.
• The forecast records a 7.2% CAGR from 2026 to 2036, supported by demand for enteral feeding and medication administration in home-care settings.

Source: Fact.MR analysis. Updated Oct 28, 2026

What are the defining numbers behind Enteral Home Use Syringes Market growth?

USD 351.9 million absolute opportunity between 2026 and 2036.

• Demand Drivers in the Market
  • Patients who cannot meet their nutritional requirements through oral intake may require tube feeding at home. Enteral syringes are used to administer prescribed nutrition, water and medications through compatible feeding tubes. A suitable supporting statistic is India's expanding older population. In March 2026, the Government of India reported that the population aged 60 years and above is projected to rise from 100 million in 2011 to 230 million by 2036, increasing its share of the population from 8.4% to 14.9% [1].
  • Chronic illnesses and conditions that impair swallowing can increase the need for enteral feeding equipment. A March 2026 update from India's Ministry of Health and Family Welfare reported that, as of February 2026, 4.69 crore people had been diagnosed with diabetes and 7.01 crore with hypertension under the National Programme for Prevention and Control of Non-Communicable Diseases [2].
  • Increase in demand for accurate and safer medication administration has driven the market growth. Enteral syringes are used to deliver prescribed liquid medications through feeding tubes. The need for appropriate connectors, clear measurement markings and accurate administration supports demand for purpose-designed products. Safety-focused connector designs, including ENFit-compatible systems, also encourage healthcare providers and caregivers to select syringes designed for enteral use.
• Key Segments Analyzed
  • By Product Type: Enteral Feeding Syringes will account for 58.5% of the market in 2026, reflecting their role in delivering prescribed feeds and fluids through enteral access systems.
  • By Application: Chronic Illness Management leads with 52.0% of the market in 2026, driven by recurring administration needs among patients receiving ongoing nutritional or medication support.
  • By End-User: Home Healthcare holds prominent share of 46.2% in 2026, consistent with the market's focus on syringe use outside conventional hospital settings.
  • By Distribution Channel: Hospital Pharmacies account for 35.8% of the market in 2026, supported by their role in supplying prescribed medical devices and associated feeding products.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “The enteral home use syringes market is closely linked to the practical requirements of long-term nutritional support and medication administration. Manufacturers need to balance accurate measurement, connector compatibility, ease of handling, and clear caregiver instructions. Product selection also depends on the prescribed feeding protocol and whether a single-use or single-patient-use design is appropriate.”
• Strategic Implications
  • Manufacturers need to specify syringe capacity, connector design, intended use, and relevant handling instructions clearly across product documentation.
  • Home-care providers must train patients and caregivers in the correct administration procedure, hygiene, storage, and replacement schedule.
  • Distributors should maintain availability across common syringe capacities and distinguish single-use products from single-patient-use alternatives.
  • Healthcare professionals need to match syringe design and capacity to the prescribed enteral feeding or medication protocol.
  • Purchasing teams should assess device compatibility, supply reliability, product quality, and the total cost of use rather than comparing products on unit price alone.

Germany is set to record 7.8% CAGR through 2036. Brazil is set to post 7.1%, followed by the USA at 6.5%. The UK is estimated to advance at 5.8%, while Japan is forecast at 5.1%.

Fact.MR finds that Enteral Feeding Syringes leads Product Type at 58.5%; Chronic Illness Management Leads Application at 52.0%; Home Healthcare Leads End-User at 46.2%; and Hospital Pharmacies leads Distribution Channel at 35.8%.

Which Product Type dominates?

Enteral Feeding Syringes are set to hold 58.5% share in 2026.

Source: Fact.MR analysis. Updated Oct 28, 2026

Enteral feeding syringes are designed to deliver prescribed nutrition, fluids, and medication through compatible enteral access systems. Their selection depends on the required capacity, connector type, feeding method, and instructions provided by the treating professional. Oral syringes serve a different administration route and are used to measure and deliver liquid medication or nutrition by mouth. The two categories need to remain distinct because their intended use and connector requirements can differ.

What leads the Application segment?

Chronic Illness Management is set to represent 52.0% share in 2026.

Source: Fact.MR analysis. Updated Oct 28, 2026

Chronic illness management includes ongoing care in which patients may require enteral nutrition or prescribed liquid medication over an extended period. Syringes support measured administration within the patient's care plan. Post-surgical care, pediatric care, and geriatric care also contribute to demand, with the required syringe capacity and handling instructions varying by patient and clinical protocol.

How does End-User shape demand?

Home Healthcare is likely to account for 46.2% share in 2026.

Source: Fact.MR analysis. Updated Oct 28, 2026

Home healthcare depends on devices that patients and caregivers can use correctly after appropriate training. Syringes need readable measurement markings, suitable connectors, and instructions that fit the prescribed feeding or medication routine. Hospitals and clinics remain relevant because they initiate treatment, train caregivers, and support transitions to home-based care. Other end-users may include additional institutional or care settings covered by the market definition.

What is the leading Distribution Channel?

Hospital Pharmacies are set to represent 35.8% share in 2026.

Source: Fact.MR analysis. Updated Oct 28, 2026

Hospital pharmacies can supply syringes as part of prescribed feeding and medication regimens, including products required when patients leave hospital for home care. Online pharmacies and retail pharmacies provide additional routes for replenishment, subject to local regulations and product availability. Distribution performance depends on dependable stock, accurate product identification, and access to compatible devices.

Growing demand for home-based enteral nutrition and safer medication administration supports adoption, while product costs and risks of incorrect handling constrain market growth.

Drivers Impact Analysis

Source: Fact.MR analysis. Updated Oct 28, 2026

Opportunity Impact Analysis

Source: Fact.MR analysis. Updated Oct 28, 2026

Restraints Impact Analysis

Source: Fact.MR analysis. Updated Oct 28, 2026

Source: Fact.MR analysis. Updated Oct 28, 2026

What supports Germany adoption?

7.8% CAGR, reflecting the forecast for enteral home-care syringe demand.

Germany's market outlook depends on demand for medical devices used in nutritional support, medication delivery, and continuing patient care outside hospitals. Syringe selection depends on the prescribed feeding protocol, connector compatibility, and the availability of suitable products through medical supply channels.

How is Brazil developing enteral home-care syringe adoption?

7.1% CAGR, supported by expansion in home-based care.

Brazil's market opportunity depends on access to feeding accessories and medical devices across hospitals, outpatient services, and home-care settings. Distribution reliability and the availability of compatible products influence whether patients and caregivers can maintain prescribed feeding routines. Manufacturers and distributors also need to account for local product registration and supply requirements.

What supports United States adoption?

6.5% CAGR, driven by the rising home-care enteral device demand.

The United States has an established market for enteral feeding accessories. BD lists enteral syringes in its product portfolio, while Avanos markets NEOMED At Home reusable oral/enteral syringes for non-clinical settings and single-patient use [3] [4]. The availability of dedicated home-use enteral syringes demonstrates product options for feeding and medication administration outside hospitals. Manufacturer specifications establish intended use and product availability; market growth remains a Fact.MR forecast.[3][4]

How is the United Kingdom building adoption?

5.8% CAGR, reflecting the forecast for home-care syringe use.

The UK enteral home use syringes market is expanding due to increasing adoption of home enteral nutrition, rising demand for ENFit-compatible devices, and growing use of enteral syringes for precise feeding and medication delivery. Greater emphasis on connector safety, prevention of misconnections, and efficient nutritional support for ageing patients is further supporting market growth.

The UK market includes products designed specifically for use at home. GBUK's ISOSAF Enteral Home range includes several syringe capacities for liquid medication, enteral feeding, and hydration. Its product portfolio includes single-patient-use options, making it directly relevant to the market's home-care focus [5].

What supports Japan adoption?

5.1% CAGR, supported by rising demand for long-term nutritional support and the need for reliable enteral feeding equipment for elderly patients.

Japan's opportunity depends on the availability of suitable enteral accessories and the ability of healthcare providers to support patients requiring ongoing nutritional assistance. Compatibility with feeding systems remains important alongside caregiver training and reliable product availability. Demand for enteral syringes is also supported by the need for accurate feeding and medication delivery in home-care settings.

Fact.MR finds that B. Braun Melsungen AG, GBUK Group, Avanos Medical, Inc., Medline Industries, LP, Medela, Amsino International, Inc., and Becton, Dickinson and Company (BD) are profiled across the enteral feeding and medical device value chain.

B. Braun Melsungen AG and Amsino International, Inc. participate in the supply of enteral feeding products and related medical devices. GBUK Group and Avanos Medical, Inc. serve medical device markets with products relevant to enteral care. Medline Industries, LP and Becton, Dickinson and Company offer broader healthcare product portfolios, while Medela is active in medical technology and feeding-related solutions. Individual product availability and suitability should be verified against specific home enteral feeding requirements.

Commercial competition depends on syringe compatibility, accurate dose delivery, ease of handling, patient safety, and dependable distribution. Home healthcare providers and caregivers require products that support practical feeding routines, while healthcare professionals prioritize appropriate connections, clear graduations, and reduced risks of administration errors.

Key companies include B. Braun Melsungen AG; GBUK Group; Avanos Medical, Inc.; Medline Industries, LP; Medela; Amsino International, Inc.; and Becton, Dickinson and Company (BD).

• B. Braun Melsungen AG
• GBUK Group
• Avanos Medical, Inc.
• Medline Industries, LP
• Medela
• Amsino International, Inc.
• Becton, Dickinson and Company (BD)

• [1] Ministry of Social Justice and Empowerment. (2026, March 24). Growth of elderly population. Press Information Bureau, Government of India.
• Official PIB source
• [2] Ministry of Health and Family Welfare. (2026, March 23). Update on NP-NCD: 8.73 crore women screened for cervical cancer; 93,062 cases diagnosed under NP-NCD. Press Information Bureau, Government of India.
• Official PIB source
• [3] Becton, Dickinson and Company. (n.d.). BD® Enteral Syringe with clear barrel and BD UniVia™ Connector sterile, single use, 10 mL. Official BD product page
• [4] Avanos Medical, Inc. (n.d.). NEOMED™ At Home OTC reusable syringes. Official Avanos product page
• [5] GBUK Group. (n.d.). ISOSAF® Enteral Home. Official GBUK product page
• [6] Organisation for Economic Co-operation and Development. (2025, November 13). Health expenditure per capita. In Health at a Glance 2025: OECD Indicators. OECD Publishing.
• Official OECD source
• [7] Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals. (2026, March 13). Medical devices manufacturers. Press Information Bureau, Government of India.
• Official PIB source

• The report describes the use of enteral home-care syringes across the specified product types and applications.
• Segment analysis compares the leading segments and their 2026 shares.
• Country analysis discusses Germany, Brazil, the USA, the UK, and Japan using the CAGR.
• The competitive overview profiles seven companies and identifies publicly documented product offerings.
• Distribution analysis distinguishes hospital pharmacies from online pharmacies, retail pharmacies, and other channels.
• Strategic analysis considers product compatibility, caregiver instructions, device availability, and home-care requirements.

The market covers syringes intended to measure and administer prescribed enteral nutrition, fluids, and medication within the defined home-care market. It includes enteral feeding syringes and oral syringes, with demand assessed across chronic illness management, post-surgical care, pediatric care, geriatric care, and other applications. The analysis considers home healthcare and institutional end-users alongside the specified distribution channels.

What is included in the scope?

Included products are enteral feeding syringes and oral syringes that fall within the market definition. The analysis considers single-use and single-patient-use products, compatible enteral connectors, different syringe capacities, and the distribution of relevant devices for home-care use. Products are assessed according to their documented intended use and applicable market availability.

What is excluded from the scope?

The analysis excludes general-purpose injection syringes that are not intended for enteral or oral administration. Enteral feeding pumps, feeding tubes, nutrition formulas, and other accessories are excluded as separate product categories unless specifically included in the defined syringe revenue boundary. Hospital-only products that do not meet the home-use market definition are also outside the narrowly defined scope.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

• Primary Research: Primary research includes discussions with manufacturers, service providers, technology developers, distributors, end users, and subject-matter experts. These conversations examine purchasing priorities, product adoption, operational challenges, approval requirements, competitive positioning, and the factors that influence wider market acceptance.
• Desk Research: Desk research covers government statistics, regulatory publications, company filings, trade data, technical studies, industry associations, standards, public policy, and other authoritative sources. Every source used in the analysis is documented in the bibliography.
• Market Sizing and Forecasting: Market estimates combine historical performance, demand indicators, pricing and volume trends, segment shares, company participation, country-level growth, adoption patterns, investment activity, and barriers to market expansion.
• Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory changes, trade patterns, and industry developments. Regular updates review new product launches, capacity changes, partnerships, approvals, and shifts in commercial adoption.